CN105085927A - Tri-block copolymer, preparation method thereof and eye drop prepared from tri-block copolymer - Google Patents
Tri-block copolymer, preparation method thereof and eye drop prepared from tri-block copolymer Download PDFInfo
- Publication number
- CN105085927A CN105085927A CN201510510461.8A CN201510510461A CN105085927A CN 105085927 A CN105085927 A CN 105085927A CN 201510510461 A CN201510510461 A CN 201510510461A CN 105085927 A CN105085927 A CN 105085927A
- Authority
- CN
- China
- Prior art keywords
- peg
- pcl
- pei
- cooh
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229920001400 block copolymer Polymers 0.000 title abstract 6
- 229920000642 polymer Polymers 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 49
- 239000000693 micelle Substances 0.000 claims abstract description 42
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 12
- 239000012298 atmosphere Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 7
- JBFHTYHTHYHCDJ-UHFFFAOYSA-N gamma-caprolactone Chemical group CCC1CCC(=O)O1 JBFHTYHTHYHCDJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000013019 agitation Methods 0.000 claims description 5
- 239000012295 chemical reaction liquid Substances 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000007151 ring opening polymerisation reaction Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000003760 magnetic stirring Methods 0.000 claims description 4
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000012043 crude product Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 239000012074 organic phase Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000003999 initiator Substances 0.000 claims description 2
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 abstract description 17
- 210000001508 eye Anatomy 0.000 abstract description 14
- 230000004888 barrier function Effects 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 2
- 238000010364 biochemical engineering Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 11
- 229930105110 Cyclosporin A Natural products 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 7
- 238000011068 loading method Methods 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000000482 two photon fluorescence microscopy Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical fields of polymer chemistry and biochemical engineering and concretely relates to a tri-block copolymer, a preparation method thereof and an eye drop prepared from the tri-block copolymer. The tri-block copolymer has the molecular formula as follows: PEG-PCL-PEI. The preparation method comprises the steps of firstly, synthesizing PEG-PCL-OH; then, synthesizing PEG-PCL-COOH; and finally, synthesizing PEG-PCL-PEI. The tri-block copolymer disclosed by the invention can be self-assembled to form a micelle system, and furthermore, the eye drop is prepared, so that the cornea barrier is overcome to deliver a drug, the cornea permeability is relatively high, and the standing time of the drug on eyes is prolonged.
Description
Technical field
The invention belongs to polymer chemistry and biomedical engineering technology field, be specifically related to a kind of ternary block polymer and preparation method thereof and the eye drop utilizing it to make.
Background technology
Due to its ease for use, low invasion and attack with simply fill a prescription, local eye droppings is the prefered method of eye medicinal administration, particularly in treatment with cornea, eye table and anterior ocular segment relative disease.But the physiological structure that cornea is special and biochemical character limit the perviousness of medicine.In addition, the specific defense mechanism of eyes after topical, such as, shed tears, tear dilutes and tear replacement can make drug solution be reduced to 5 ~ 6 minutes at the residence time in cornea region, only the drug solution of 1-3% can infiltrate through cornea and arrive eye inner tissue.
The major cause of hyposmosis is the existence that after a medicine, medicine enters intraocular hour angle envelope barrier, is mainly manifested in corneal epithelial cell arrangement closely, and the contrary physicochemical property with lipophilic epithelial layer and hydrophilic substrate layer existed.Epithelium and matrix present different physico-chemical properties, and hydrophilic compounds is only by epithelial lining, and the movement of lipophilic compound is then limited in hypothallus.Therefore, the contrary polar structure of cornea seriously hinders medicine to enter eyeball by cornea.Therefore, the cornea penetrance strengthening eye drop is one and has one of challenging research direction in ophthalmological exploitation.
In the past few decades, amphipathic nature block polymer self-assembly polymer micelle as drug delivery system effectively solubilising insoluble drug caused increasing concern.Polymer micelle is the drug delivery system with numerous premium properties, and such as kinetics and thermodynamic stability are good, even size distribution (20 ~ 100nm), adjustable surface potential, good biocompatibility, effectively assembles and infiltration in tissue, superior Co ntrolled release performance, hypotoxicity.Recently, in order to improve the release performance of medicine, polymer nano granules has been used in the development research of dosing eyes system by investigator.Polymer nano granules drug-loading system has superior biological property, such as can biocompatibility, biodegradable, mucosa-adherent, nontoxicity and drug controlled release.The topical that medicine carrying system of polymer micelle is used for ocular drug has a good application prospect.
The particle diameter of polymer micelle and surface potential affect its two principal elements applied at ophthalmological.Small particle size and the nanoparticle of surface band positive electricity contribute to increasing the passing through property of medicine at eye.The nano-micelle of small particle size is easily through cornea barrier.The surperficial polymer micelle with positive electricity and eye are shown electronegative Saliva Orthana and be there is electrostatic interaction, show sticking property at eye table.And the non-specific electrostatic that has between positive electricity polymer micelle and electronegative cell interacts, can promote that cell is to the picked-up of nanoparticle.Therefore, the polymer micelle with positive surface charge can extend the residence time at eye, strengthens the corneal osmosis of polymer micelle medicine.Amphipathic nature block polymer PEG-poly-(6-caprolactone) (PEG-PCL) has attracted increasing concern, and the nanosized micelles of existing self-assembly nucleocapsid structure is used for medicine transmission.PEG is bioavailable polymer, as polymer micelle shell, forms hydrophilic block.Because have wetting ability, electric neutrality, chain flexibility, do not have immunogenicity, PEG is widely used in the design of amphiphilic block copolymer.PEG all has superior solubility property in water-based and oil-based solvent, thus makes macromolecule micelle effectively by cornea barrier, can increase the cornea permeability of medicine.And the degraded product of polycaprolactone has biocompatibility, can be applied for human body by food and drug administration's approval.
Summary of the invention
The object of the present invention is to provide a kind of ternary block polymer and preparation method thereof and the eye drop utilizing it to make.
For achieving the above object, the technical scheme taked of the present invention is as follows:
A kind of ternary block polymer, molecular formula is: PEG-PCL-PEI, and structural formula is:
, wherein, m, n, x, y are positive integer.
Preparation method, synthetic route is as follows:
；
Namely comprise the following steps:
S1. PEG-PCL-OH is synthesized: take PEG-OH as initiator, Sn (Oct)
2for catalyzer, catalysis causes 6-caprolactone ring-opening polymerization; After reaction terminates, aftertreatment obtains PEG-PCL-OH;
S2. PEG-PCL-COOH:PEG-PCL-OH and succinyl oxide is synthesized, under inert atmosphere, reactive esterify hydroxy; After reaction terminates, aftertreatment obtains PEG-PCL-COOH;
S3. synthesize PEG-PCL-PEI:PEG-PCL-COOH, NHS, DCC and PEI in chloroform, under inert atmosphere, stirring at room temperature is reacted; After reaction terminates, aftertreatment obtains PEG-PCL-PEI;
In S1-S3, the structural formula of PEG-PCL-OH, PEG-PCL-COOH, PEG-PCL-PEI is respectively:
、
、
。
Particularly, step is:
S1. synthesize PEG-PCL-OH: first, PEG-OH and 6-caprolactone are put into flask, drying under reduced pressure; Then, in flask, Sn (Oct) is added under an inert atmosphere
2, then sealed flask be immersed in oil bath, 110 ~ 120 DEG C of ring-opening polymerization 20 ~ 28h; Separating reaction liquid, is dissolved in solids in THF, adds ether, collecting precipitation, namely obtain PEG-PCL-OH after drying;
S2. PEG-PCL-COOH is synthesized: PEG-PCL-OH and maleic anhydride are dissolved in chloroform dried in advance, under an inert atmosphere, 60 ~ 80 DEG C of stirring and refluxing reaction 60 ~ 84h; Separating reaction liquid, solids obtains crude product through ether sedimentation purifying, is again dissolved in DCM; DCM solution is first used salt acid elution, then washs by saturated NaCl solution; Then, isolate organic phase, by dried over mgso, and filter, add ether, collecting precipitation, after drying, namely obtain PEG-PCL-COOH;
S3. PEG-PCLPEG-PCL-PEI is synthesized: be dissolved in by PEG-PCL-COOH and NHS in chloroform, and be placed on and be furnished with in the flask of magnetic stirring bar, flask is placed in ice-water bath, add DCC, then after flask being sealed under an inert atmosphere, stir, add the chloroformic solution of PEI, continue to stir, more at room temperature stir 20 ~ 28h; Filter, filtrate joined in excessive ether, collecting precipitation thing, namely obtains PEG-PCL-PEI after drying.
The eye drop that ternary block polymer described in utilization is made, prepares: be dissolved in by the treatment ophthalmic diseases common drug of the PEG-PCL-PEI of 10 ~ 20mg and 0.5 ~ 1mg in the mixed solvent that 1 ~ 2mL is made up of with volume ratio 1:1 ~ 3 methyl alcohol and acetonitrile by the following method; Then, under ultrasonic agitation, be added drop-wise to by mixed solution in the PBS of 20 ~ 30mL, vacuum distilling removing organic solvent, repeated washing concentrates the free medicine of removing, filters to obtain drug-carrying polymer micelle; This drug-carrying polymer micelle and physiological saline mix with the volume ratio of 1:9 ~ 11, namely make eye drop.
Compared with prior art, beneficial effect of the present invention:
Ternary block polymer of the present invention self-assembly can be formed micellar system and then makes eye drop, overcomes corneal dystrophies and transmits medicine, have higher corneal permeability, extend the residence time of medicine at eye.
Accompanying drawing explanation
Fig. 1: PEG-OH, PEG-PCL-OH, PEG-PCL-COOH and PEG-PCL-PEI's
1hNMR spectrogram.
The infrared spectrum of Fig. 2: PEG-PCL-COOH (a) and PEG-PCL-PEI (b).
Fig. 3: polymer micelle medicine carrying process schematic.
Fig. 4: the electron microscopic picture (scale 200nm) of (a) polymer micelle; The In-vitro release curves of (b) drug-carrying polymer micelle.
Cornea after Fig. 5: C57BL/6 mouse topical detects figure through behavior Two Photon Fluorescence.
Embodiment
Below in conjunction with Figure of description and specific embodiment, set forth the present invention further.These embodiments are only not used in for illustration of the present invention and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to this area normal condition or the condition according to manufacturer's suggestion.Change and the replacement of any unsubstantiality that those skilled in the art does on basis of the present invention all belong to the present invention's scope required for protection.
The synthesis of embodiment 1 ternary block polymer
Ternary block polymer, molecular formula is: PEG-PCL-PEI, and structural formula is:
。
Synthesis step:
S1. synthesize PEG-PCL-OH: first, by 10.0gPEG-OH(MW:2000) and 20.6g 6-caprolactone put into flask, 70 DEG C of drying under reduced pressure 2h; Then, in flask, add the Sn (Oct) accounting for 6-caprolactone 0.1mol% under an argon atmosphere
2, then sealed flask be immersed in oil bath, 115 DEG C of ring-opening polymerization 24h; Separating reaction liquid, is dissolved in solids in THF, adds ether sedimentation and carries out purifying, collecting precipitation twice, namely obtain PEG-PCL-OH, productive rate: >96% after 40 DEG C of vacuum-dryings;
S2. synthesizing PEG-PCL-COOH:1mmolPEG-PCL-OH and 10mmol maleic anhydride is dissolved in 100ml chloroform dried in advance, be placed in the two neck flasks that magnetic stirring bar and reflux exchanger are housed, by mixture under an argon atmosphere, 70 DEG C of stirring and refluxing reaction 72h; Filtering reacting liquid, solids obtains crude product through ether sedimentation purifying, is again dissolved in DCM; First used by DCM solution hydrochloric acid (10%, v/v) to wash 3 times, then wash 4 times by saturated NaCl solution; Then, isolate organic phase, by dried over mgso, and filter, add ether, collecting precipitation, at 50 DEG C, vacuum-drying is to constant weight, to eliminate water and maleic anhydride residue, obtains PEG-PCL-COOH, productive rate: >90%;
S3. PEG-PCL-PEI is synthesized: be dissolved in by 1.84gPEG-PCL-COOH and 85mgNHS in 20ml chloroform, and be placed on and be furnished with in the flask of magnetic stirring bar, flask is placed in ice-water bath, add 148mgDCC, then after flask being sealed under an argon atmosphere, 0 DEG C stir 1 hour, then add containing 1.26gPEI(MW:1800) chloroformic solution 10ml, continue stirring 1 hour at 0 DEG C, more at room temperature stir 24 hours; Filter, filtrate is joined in excessive ether, collecting precipitation thing, namely obtain PEG-PCL-PEI after ambient temperature in vacuum drying, productive rate: >85%;
In S1-S3, PEG-OH, PEG-PCL-OH, PEG-PCL-COOH and PEG-PCL-PEI's
1hNMR spectrogram is shown in Fig. 1; The infrared spectrum of PEG-PCL-COOH and PEG-PCL-PEI is shown in Fig. 2 (a) and (b).
In Fig. 1: the methene proton of spike owing to PEG block appearing at 3.64ppm; The type signal of the methene proton of PCL block appears at 1.32,1.56,2.31,4.06ppm; Strong and the wide absorption peak observed in 2.5 ~ 2.9ppm is belonged to the methylene radical of PEI.
1hNMR result shows, has successfully synthesized ternary block polymer PEG-PCL-PEI.
In Fig. 2: the charateristic avsorption band of PEG and PCL is respectively at 1190cm
-1(S, VC-O) and 1726cm
-1(S, VC=O), obviously, these two PEG and PCL blocks are present in intermediate pre-polymer PEG-PCL-COOH and final copolymer p EG-PCL-PEI; Two large about 1644cm
-1, 1562cm
-1locate new, that strong absorption belongs to amido linkage (S, vamide, C=O) charateristic avsorption band; In addition, 3300cm
-1locate the charateristic avsorption band that strong and wide absorption belongs to amine (S, VN-H).
The block composition of ternary block polymer PEG-PCL-PEI passes through
1the integrated intensity at the peak of HNMR calculates, and three blocks have the molecular weight of 2000,2500 and 1800 respectively, and polymkeric substance can be expressed as PEG
2000-PCL
2500-PEI
1800.
performance test
0, medicine prepares
Blank polymer micella: 10mg embodiment 1PEG-PCL-PEI is dissolved in the mixed solvent that 2mL is made up of with volume ratio 1:1 methyl alcohol and acetonitrile; Then, under ultrasonic agitation, mixed solution is added drop-wise in the PBS (pH7.2) of 20mL, by rotary evaporation devices vacuum distilling removing organic solvent, again by ultrafiltration centrifugal filter device (molecular weight cut-off: 100,000Da) concentrated 3 times of repeated washing, further mistake filters large polymkeric substance, obtains blank polymer micelle.
FDA polymer micelle and FDA polymer micelle eye drop: by 10mg embodiment 1PEG-PCL-PEI and 0.5mgFDA(fluorescein diacetate Fluoresceindiacetate) be dissolved in the mixed solvent that 2mL is made up of with volume ratio 1:1 methyl alcohol and acetonitrile; Then, under ultrasonic agitation, mixed solution is added drop-wise in the PBS (pH7.2) of 20mL, by rotary evaporation devices vacuum distilling removing organic solvent, again by ultrafiltration centrifugal filter device (molecular weight cut-off: 100,000Da) repeated washing concentrates 3 times to remove free FDA, and further mistake filters large polymkeric substance or FDA aggregate, obtains the polymer micelle of load FDA; This polymer micelle and physiological saline mix with the volume ratio of 1:9, namely make FDA polymer micelle eye drop.
Ciclosporin A polymer micelle and ciclosporin A polymer micelle eye drop: preparation method, substantially with polymer micelle and the FDA polymer micelle eye drop of load FDA, only need replace FDA with ciclosporin A.
FDA nano particle or micron particle eye drop: 0.5mgFDA nano particle or micron particle (prior art preparation) are dissolved in the mixed solvent that 2mL is made up of with volume ratio 1:1 methyl alcohol and acetonitrile; Then; under ultrasonic agitation; mixed solution is added drop-wise in the PBS (pH7.2) of 20mL; by rotary evaporation devices vacuum distilling removing organic solvent; again by ultrafiltration centrifugal filter device (molecular weight cut-off: 100; 000Da) repeated washing concentrates 3 times to remove free FDA, and further mistake filters large FDA aggregate, obtains FDA nano particle or micron particle eye drop.
1, the particle diameter of polymer micelle and surface potential detection
Measure the particle diameter of blank polymer micella with Zeta-Plus current potential particle instrument (BrookenHaven), laser wavelength of incidence λ=532nm, incidence angle θ=90 °, temperature is 25 DEG C; Get the mean value of three observed values.The trace detection sample pool that ζ surface potential uses Brookhaven special, to increase the accuracy detecting data; Often organize sample, all get the mean value measured for 5 times.
Measuring result shows: Inventive polymers micella has relatively little particle diameter (for 27.74nm) and the surperficial positive potential of 12.12mv.Positive electricity polymer micelle can load hydrophobic drug, as shown in Figure 3.
The form of polymer micelle is measured by scanning electron microscope, the results are shown in Figure 4a, is uniform globosity.
2, the mensuration of drug-carrying polymer micelle drug loading
The drug loading of drug-carrying polymer micelle Chinese traditional medicine ciclosporin A is defined as the weight percent of medicine in micella.In order to determine drug loading, pre-weighed freeze-drying micella, is dissolved in acetonitrile/methanol (1/1, volume ratio) again.The concentration of sample is detected with HPLC.The chromatographic column model that wherein HPLC is used is Waters2695 company, is furnished with X-BridgeTMC18column (3.5 μm, 3.0mm × 150mm, Waters, USA) andUV/vis detector, moving phase is acetonitrile and water (V:V=79:21), and flow velocity is 0.8mL/min, column temperature is 50 DEG C, and injected sample amount is 20 μ L.Calculate according to set ciclosporin A typical curve.Drug loading (DLC, % by weight) and medicine carrying efficiency (DLE, % by weight) are according to following formulae discovery:
Drug quality/polymer latex the beam quality of DLC=(institute load) × 100%;
The original quality that feeds intake of drug quality/medicine of DLE=(institute load) × 100%.
Result shows: the drug loading (DLC) of ciclosporin A polymer micelle of the present invention be 3.47% and medicine carrying efficiency (DLE) be 75.37%.
3, vitro drug release behavioral study
Body is utilized to balance the vitro drug release behavior of reverse dialysis bag technique research drug-carrying polymer micelle.Detailed process is as follows: joined by ciclosporin A polymer micelle in the dialysis tubing of the 1ml of predetermined number respectively, then dialysis tubing is dipped into the PBS(pH7.2 of 200ml phosphate citrate buffer) in, shake at the incubator shaking tables of 35 DEG C (the permanent scientific & technical corporation of Chinese Shanghai hundred million).At predetermined time point, take out dialysis tubing, the content of high-efficient liquid phase color spectrometry medicine ciclosporin A, calculates the cumulative release amount of different time points.When analyzing ciclosporin A release shape and being, with the time to the mapping of ciclosporin A cumulative release amount, obtain the curve of external ciclosporin A from the intrafascicular release of polymer latex.
The In-vitro release curves of drug-carrying polymer micelle is shown in Fig. 4 b, known: release profiles has typical two-phase release mode: initial release fast, and continuing slow releasing subsequently time expand can reach a few hours.Drug release, reached 44.8% in 12 hours, can reach 31.7% in 2 Hours drug releases.
4, animal prepares and Two Photon Fluorescence imaging in body
By peritoneal injection vetanarcol (85 mgs/kg of body weight) (Sigma-Aldrich company, the U.S.) by C57BL/6 mouse anesthesia.Utilize plastics eyecup to cover on the eyes of mouse, utilize Vaseline to seal.Then by FDA polymer micelle eye drop instillation eyecup, leave standstill half an hour, then use salt solution rinsing three corneas of 0.9%, mouse is placed on a plastic plate, head and four limbs are fixed with adhesive tape, eyecup soaks with 0.9% salt brine solution and then carries out two-photon 3D imaging in body.Use Zeiss LSM780NLO fluoroscopic imaging systems (CarlZeissMicroImagingGmbH, Jena, Germany), this system utilizes Zeiss operating system (Zen2010; CarlZeissMicroImagingGmbH).
All imagings are all use × 20 (Plan-Apochromat, NA=1.0; CarlZeiss) carry out under moisture film soaks.The non-detector that moves back of double reflected light is adopted two-photon imaging signal to be detected respectively.Laser power used is 24 ~ 28% of maximum laser power.Utilize aperture to be the environment that this application program arranges maximum opening, and by the step-length of sample by 2 millimeters of z-axis, scan to produce the 3-D data set extended from corneal endothelium to epithelial surface.Image sequence is designated as 12 respectively, the image of 512 × 512 pixels.The scanning speed used in research is every frame 968.14 milliseconds.Cornea three-dimensional data is collected other region by from center.
With FDA nano particle and FDA micron particle eye drop medicine in contrast, after the eye droppings of local, medicine is shown in Fig. 5 at the intraocular distribution Two Photon Fluorescence detection figure of mouse.After dripping FDA polymer micelle eye drop, the dark corneal osmosis behavior of fluorescent drug can be observed, and there is time-dependent manner, after some medicine when 15 minutes, fluorescence only exists only in corneal epithelium, and fluorescence spreads from epithelium to the hypothallus of cornea 30 minutes time; 60 minutes time, the fluorescence intensity ratio epithelial lining of hypothallus is strong.And the fluorescence of control group eye drop (FDA nano particle and FDA micron particle) only exists only in corneal epithelium, and do not change along with the prolongation of time.Results of comparison shows: polymer micelle effectively can overcome corneal dystrophies, and releasing theory medicine is to cornea deep layer.
Claims (4)
1. a ternary block polymer, it is characterized in that molecular formula is: PEG-PCL-PEI, structural formula is:
, wherein, m, n, x, y are positive integer.
2. prepare a method for ternary block polymer as claimed in claim 1, it is characterized in that comprising the following steps:
S1. PEG-PCL-OH is synthesized: take PEG-OH as initiator, Sn (Oct)
2for catalyzer, catalysis causes 6-caprolactone ring-opening polymerization; After reaction terminates, aftertreatment obtains PEG-PCL-OH;
S2. PEG-PCL-COOH:PEG-PCL-OH and succinyl oxide is synthesized, under inert atmosphere, reactive esterify hydroxy; After reaction terminates, aftertreatment obtains PEG-PCL-COOH;
S3. synthesize PEG-PCL-PEI:PEG-PCL-COOH, NHS, DCC and PEI in chloroform, under inert atmosphere, stirring at room temperature is reacted; After reaction terminates, aftertreatment obtains PEG-PCL-PEI;
In S1-S3, the structural formula of PEG-PCL-OH, PEG-PCL-COOH, PEG-PCL-PEI is respectively:
、
、
。
3. preparation method as claimed in claim 2, is characterized in that concrete steps are:
S1. synthesize PEG-PCL-OH: first, PEG-OH and 6-caprolactone are put into flask, drying under reduced pressure; Then, in flask, Sn (Oct) is added under an inert atmosphere
2, then sealed flask be immersed in oil bath, 110 ~ 120 DEG C of ring-opening polymerization 20 ~ 28h; Separating reaction liquid, is dissolved in solids in THF, adds ether, collecting precipitation, namely obtain PEG-PCL-OH after drying;
S2. PEG-PCL-COOH is synthesized: PEG-PCL-OH and maleic anhydride are dissolved in chloroform dried in advance, under an inert atmosphere, 60 ~ 80 DEG C of stirring and refluxing reaction 60 ~ 84h; Separating reaction liquid, solids obtains crude product through ether sedimentation purifying, is again dissolved in DCM; DCM solution is first used salt acid elution, then washs by saturated NaCl solution; Then, isolate organic phase, by dried over mgso, and filter, add ether, collecting precipitation, after drying, namely obtain PEG-PCL-COOH;
S3. PEG-PCLPEG-PCL-PEI is synthesized: be dissolved in by PEG-PCL-COOH and NHS in chloroform, and be placed on and be furnished with in the flask of magnetic stirring bar, flask is placed in ice-water bath, add DCC, then after flask being sealed under an inert atmosphere, stir, add the chloroformic solution of PEI, continue to stir, more at room temperature stir 20 ~ 28h; Filter, filtrate joined in excessive ether, collecting precipitation thing, namely obtains PEG-PCL-PEI after drying.
4. the eye drop utilizing ternary block polymer as claimed in claim 1 to make, is characterized in that preparing by the following method: be dissolved in by the treatment ophthalmic diseases common drug of the PEG-PCL-PEI of 10 ~ 20mg and 0.5 ~ 1mg in the mixed solvent that 1 ~ 2mL is made up of with volume ratio 1:1 ~ 3 methyl alcohol and acetonitrile; Then, under ultrasonic agitation, be added drop-wise to by mixed solution in the PBS of 20 ~ 30mL, vacuum distilling removing organic solvent, repeated washing concentrates the free medicine of removing, filters to obtain drug-carrying polymer micelle; This drug-carrying polymer micelle and physiological saline mix with the volume ratio of 1:9 ~ 11, namely make eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510510461.8A CN105085927B (en) | 2015-08-19 | 2015-08-19 | A kind of ternary block polymer and preparation method thereof and the eye drops being made using it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510510461.8A CN105085927B (en) | 2015-08-19 | 2015-08-19 | A kind of ternary block polymer and preparation method thereof and the eye drops being made using it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105085927A true CN105085927A (en) | 2015-11-25 |
| CN105085927B CN105085927B (en) | 2017-08-04 |
Family
ID=54567316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510510461.8A Expired - Fee Related CN105085927B (en) | 2015-08-19 | 2015-08-19 | A kind of ternary block polymer and preparation method thereof and the eye drops being made using it |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105085927B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214682A (en) * | 2016-09-06 | 2016-12-14 | 河南省眼科研究所 | Tripterine application in preparing anti-corneal graft rejection eye drop preparation |
| CN106265682A (en) * | 2016-09-06 | 2017-01-04 | 河南省眼科研究所 | Tripterine is at preparation suppression alkali burn cornea rebirth blood vessel and promotes the application in corneal alkali burn healing eye drop preparation |
| CN106957434A (en) * | 2017-05-09 | 2017-07-18 | 天津科技大学 | Triblock copolymer and porous laminated support and preparation method thereof |
| CN108721223A (en) * | 2017-04-24 | 2018-11-02 | 暨南大学 | A kind of glutathione response type is double to carry pharmaceutical polymer micella and the preparation method and application thereof |
| CN117752617A (en) * | 2023-12-29 | 2024-03-26 | 四川大学华西医院 | Application of mPEG-PCL nanoparticles modified with amphiphilic cationic substances in the preparation of drugs for the treatment of retinal diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631678A (en) * | 2012-04-18 | 2012-08-15 | 北京大学 | Triblock polymer carrier containing polyarginine as well as preparation method and application thereof |
| CN102850532A (en) * | 2012-09-21 | 2013-01-02 | 浙江大学 | Thermo-sensitive self-assembled tri-block copolymer, pharmaceutical composition, and preparation method and application of pharmaceutical composition |
| CN104069507A (en) * | 2014-06-11 | 2014-10-01 | 广州吉家庄生物科技有限公司 | High-strength supramolecular hydrogel, as well as preparation method and application thereof |
-
2015
- 2015-08-19 CN CN201510510461.8A patent/CN105085927B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631678A (en) * | 2012-04-18 | 2012-08-15 | 北京大学 | Triblock polymer carrier containing polyarginine as well as preparation method and application thereof |
| CN102850532A (en) * | 2012-09-21 | 2013-01-02 | 浙江大学 | Thermo-sensitive self-assembled tri-block copolymer, pharmaceutical composition, and preparation method and application of pharmaceutical composition |
| CN104069507A (en) * | 2014-06-11 | 2014-10-01 | 广州吉家庄生物科技有限公司 | High-strength supramolecular hydrogel, as well as preparation method and application thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106214682A (en) * | 2016-09-06 | 2016-12-14 | 河南省眼科研究所 | Tripterine application in preparing anti-corneal graft rejection eye drop preparation |
| CN106265682A (en) * | 2016-09-06 | 2017-01-04 | 河南省眼科研究所 | Tripterine is at preparation suppression alkali burn cornea rebirth blood vessel and promotes the application in corneal alkali burn healing eye drop preparation |
| CN106214682B (en) * | 2016-09-06 | 2019-04-26 | 河南省眼科研究所 | Celastrol is preparing the application in anti-corneal graft rejection eye drop preparation |
| CN106265682B (en) * | 2016-09-06 | 2019-05-10 | 河南省眼科研究所 | Celastrol inhibits alkali burn cornea rebirth blood vessel in preparation and promotes the application in Corneal Alkali Burns healing eye drop preparation |
| CN108721223A (en) * | 2017-04-24 | 2018-11-02 | 暨南大学 | A kind of glutathione response type is double to carry pharmaceutical polymer micella and the preparation method and application thereof |
| CN108721223B (en) * | 2017-04-24 | 2020-03-17 | 暨南大学 | Glutathione-responsive double-drug-loading polymer micelle and preparation method and application thereof |
| CN106957434A (en) * | 2017-05-09 | 2017-07-18 | 天津科技大学 | Triblock copolymer and porous laminated support and preparation method thereof |
| CN106957434B (en) * | 2017-05-09 | 2020-05-01 | 天津科技大学 | Triblock copolymer and porous layered scaffold and preparation method thereof |
| CN117752617A (en) * | 2023-12-29 | 2024-03-26 | 四川大学华西医院 | Application of mPEG-PCL nanoparticles modified with amphiphilic cationic substances in the preparation of drugs for the treatment of retinal diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105085927B (en) | 2017-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106265510B (en) | The multistage target polymer micella and preparation method thereof of pH trigger-type drug release in a kind of tumour cell | |
| CN105085927A (en) | Tri-block copolymer, preparation method thereof and eye drop prepared from tri-block copolymer | |
| CN102906157B (en) | Derivative hyperbranched poly glycerine | |
| Sang et al. | Preparation of pH/redox dual responsive polymeric micelles with enhanced stability and drug controlled release | |
| JP7046321B2 (en) | Modified styrene-maleic anhydride copolymer and its use | |
| CN110302396B (en) | Hydrogen peroxide-responsive multifunctional liposomes and their preparation methods and applications | |
| CN103656652A (en) | Dual-sensing response type polymer nano-micelle as well as preparation method and application thereof | |
| Tian et al. | Construction of dual-functional polymer nanomaterials with near-infrared fluorescence imaging and polymer prodrug by RAFT-mediated aqueous dispersion polymerization | |
| WO2013181888A1 (en) | Environmental responsive fundamental copolymer and preparation method therefor | |
| CN106432647B (en) | PH response block polymers and its mixed micelle based on tertiary amino and application | |
| CN104116711A (en) | pH-sensitive polymeric micelle composition resisting tumor drug resistance | |
| CN110393700A (en) | Preparation and application of F3 polypeptide-directed PAMAM-based tumor drug nanocarriers | |
| CN106008964B (en) | A kind of water-soluble amino acid block copolymer and its preparation method and application | |
| Gao et al. | Hydrotropic polymer-based paclitaxel-loaded self-assembled nanoparticles: preparation and biological evaluation | |
| CN104415339A (en) | Self-assembled targeted nanometer drug carrier micelles | |
| CN111410757B (en) | A kind of preparation method of degradable and environment-responsive composite microgel | |
| CN104415342A (en) | Self-assembled drug carrier microcapsule system containing polypyrrolidone | |
| CN106146761A (en) | The nano-micelle of a kind of amphipathic multifunctional polymer and preparation thereof and application | |
| CN103977417A (en) | Preparation method of amphiphilic drug-loaded nanoparticles | |
| CN104414999A (en) | Anti-tumor targeted nanometer drug-loaded microcapsule preparation method | |
| CN103990140A (en) | Nanometer self-assembly drug carrier system | |
| KR20230111688A (en) | Reactive oxygen-sensitive ferrocene-based nanoparticles having improved stability, method for preparing the same and uses thereof | |
| CN104151509B (en) | H-type pH-sensitive degradable block copolymer and preparation method and application thereof | |
| CN103976977A (en) | Preparation of self-assembled polymer microcapsule system | |
| CN104414996A (en) | Nano self-assembly drug carrier microcapsule system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170804 |